Market Cap (In USD)
262.73 Million
Revenue (In USD)
-
Net Income (In USD)
-49.84 Million
Avg. Volume
3.45 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.1-0.32
- PE
- -10.7
- EPS
- -0.02
- Beta Value
- 0.165
- ISIN
- US23283M1018
- CUSIP
- 23283M101
- CIK
- 1175680
- Shares
- 1227740000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jacob P. Lalezari M.D.
- Employee Count
- -
- Website
- https://www.cytodyn.com
- Ipo Date
- 2006-12-13
- Details
- CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
More Stocks
-
BLUECLOUDSBlue Cloud Softech Solutions Limited
BLUECLOUDS
-
ETIL
-
012690Monalisa Co., Ltd
012690
-
ALMASMastrad Société Anonyme
ALMAS
-
IMMVFImmunovia AB (publ)
IMMVF
-
WNBD
-
SOZAPSOZAP AB (publ)
SOZAP
-
0SOMBHG Group AB (publ)
0SOM